CI, you are right! The share price will be much, much higher b4 Leronlimab is approved especially with the cancer applications so I still say we will hit 33/share on the Nasdaq. The revenue is one thing and that will be later but with the success of the trials including TNBC, the share price will fly like I said above. Nice to see you here & GLTU

HCIT